Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
AstraZeneca
Baxter
Mallinckrodt
McKinsey
Merck

Last Updated: January 23, 2020

DrugPatentWatch Database Preview

Drugs in Development Information for Pirarubicin

Join the DrugPatentWatch Referral Program
Get access to a free drug patent landscape report or a free one-month subscription

« Back to Dashboard

What is the drug development status for Pirarubicin?

Pirarubicin is an investigational drug.

There have been 20 clinical trials for Pirarubicin. The most recent clinical trial was a Phase 3 trial, which was initiated on September 1st 2012.

The most common disease conditions in clinical trials are Carcinoma, Carcinoma, Transitional Cell, and Recurrence. The leading clinical trial sponsors are Peking University People's Hospital, Sun Yat-sen University, and Peking Union Medical College Hospital.

There are two US patents protecting this investigational drug and twenty-eight international patents.

Recent Clinical Trials for Pirarubicin
TitleSponsorPhase
Combination Therapy of Anthracyclines for Children With NephroblastomaShengjing HospitalPhase 4
Apatinib Combined With Chemotherapy in the Treatment of Soft Tissue SarcomaTianjin Medical University Cancer Institute and HospitalPhase 2
Pegylated Liposomal Doxorubicin Versus Pirarubicin Plus Ifosfamide, Dacarbazine in Locally Advanced, Unresectable or Metastatic Soft-tissue SarcomaBeijing Jishuitan HospitalPhase 2/Phase 3

See all Pirarubicin clinical trials

Clinical Trial Summary for Pirarubicin

Top disease conditions for Pirarubicin
Top clinical trial sponsors for Pirarubicin

See all Pirarubicin clinical trials

US Patents for Pirarubicin

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
Pirarubicin   Start Trial Heat shock protein 70 (hsp-70) receptor ligands Duke University (Durham, NC)   Start Trial
Pirarubicin   Start Trial Compounds and their methods of use Agios Pharmaceuticals, Inc. (Cambridge, MA)   Start Trial
Pirarubicin   Start Trial Monomethylvaline compounds having phenylalanine side-chain modification at the C-terminus Seattle Genetics, Inc. (Bothell, WA)   Start Trial
Pirarubicin   Start Trial Anti-FGFR3 antibodies and methods using same Genentech, Inc. (South San Francisco, CA)   Start Trial
Pirarubicin   Start Trial Bispecific antigen-binding constructs targeting HER2 Zymeworks Inc. (Vancouver, CA)   Start Trial
Pirarubicin   Start Trial Method of diagnosing and treating cancer using B-catenin splice variants The United States of America, as represented by the Secretary, Department of Health & Human Services (Washington, DC)   Start Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for Pirarubicin

Drugname Country Document Number Estimated Expiration Related US Patent
Pirarubicin World Intellectual Property Organization (WIPO) 2015148714 2034-03-25   Start Trial
Pirarubicin Australia 2015231053 2034-03-21   Start Trial
Pirarubicin Brazil 112016021620 2034-03-21   Start Trial
Pirarubicin Canada 2943339 2034-03-21   Start Trial
Pirarubicin China 106231900 2034-03-21   Start Trial
Pirarubicin Eurasian Patent Organization 201691896 2034-03-21   Start Trial
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Express Scripts
Colorcon
Medtronic
AstraZeneca
McKinsey
Baxter

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.